Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	19668
Country	Australia

Received	2015-05-16 14:45
Peer-Review Started	2015-05-20 08:54
To Make the First Decision	2015-07-27 16:08
Return for Revision	2015-08-10 17:37
Revised	2015-08-24 12:30
Second Decision	2015-09-28 14:32
Accepted by Journal Editor-in-Chief	2015-09-29 10:47
Accepted by Executive Editor-in-Chief	2015-10-13 17:10
Articles in Press	2015-10-13 17:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-23 15:49
Publish the Manuscript Online	2015-11-12 18:51

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?
Manuscript Source	Invited Manuscript
All Author List	Bei Ye and Daniel R van Langenberg
Funding Agency and Grant Number
Corresponding Author	Dr. Daniel R van Langenberg, Department of Gastroenterology, Eastern Health, Arnold Street, Box Hill, Victoria 3128, Australia. daniel.van-langenberg@monash.edu
Key Words	Colitis; Ulcerative; Drug delivery systems; Mesalamine; Sulfasalazine; Therapeutic equivalency
Core Tip	Various formulations of oral mesalazine are available for management of mild to moderate ulcerative colitis. Selection of the most appropriate formulation requires tailoring of the therapy to the individual and must incorporate factors such as disease distribution, efficacy, side effect profile, pill burden, patient preference and health economics.
Publish Date	2015-11-12 18:51
Citation	Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther 2015; 6(4): 137-144
URL	http://www.wjgnet.com/2150-5349/full/v6/i4/137.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v6.i4.137

Full Article (PDF)	WJGPT-6-137.pdf
Full Article (Word)	WJGPT-6-137.doc
Manuscript File	19668-Review.docx
Answering Reviewers	19668-Answering reviewers.pdf
Audio Core Tip	19668-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19668-Conflict-of-interest statement.pdf
Copyright License Agreement	19668-Copyright assignment.pdf
Peer-review Report	19668-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19668-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19668-Scientific misconduct check.pdf
Scientific Editor Work List	19668-Scientific editor work list.pdf